Findings from Case Western Reserve University Provides New Data about Androgens (Small- Molecule Disruption of Androgen Receptor-dependent Chromatin Clusters).

A report from Case Western Reserve University discusses the role of androgens in metastatic castration-resistant prostate cancer (mCRPC) and the limitations of current treatments like enzalutamide. The study introduces AR antagonists BG-15a and BG-15n, which show promise in down-regulating AR-target genes and reducing cell and tumor growth in mCRPC models. The research suggests that these molecules disrupt chromatin clusters, offering potential as new agents for treating relapsed AR-driven mCRPC tumors. [Extracted from the article]